It may be sensible to routinely screen for and document comorbid AD and family history of AD in all patients with OCD and TD/CTD, particularly – but not exclusively – in those presenting with the constellation of symptoms commonly referred to as PANS or PANDAS. Long-term follow-up of these patients may provide useful clues regarding their prognosis, compared to patients without a personal or familial link to AD. Whether patients with an AD link respond differently or preferentially to conventional evidence-based treatments is another interesting question for the future. As knowledge advances, it may be possible to identify robust biomarkers to help guide the clinical management of those patients.
